Akebia Therapeutics, Inc. cotiza a 0.77 USD y tiene una capitalización bursátil de $213M. En los últimos 12 meses ha facturado $219M con un margen de flujo de caja libre del 28.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.03 | $-0.03 | $-0.05 |
| Estimado | $-0.03 | $-0.02 | $-0.02 | $-0.04 |
| Sorpresa | — | -50.0% | -50.0% | -25.0% |
| Métrica | AKBA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 83.3% | 57.0% | +26.3% |
| Operating Margin | 9.9% | -38.6% | +48.6% |
| Net Margin | -2.3% | -33.6% | +31.3% |
| FCF Margin | 28.7% | -13.9% | +42.5% |
| ROE | -16.4% | -40.4% | +24.0% |
| ROA | -1.4% | -32.0% | +30.6% |
| Current Ratio | 1.55 | 2.84 | -1.29 |
| Debt / Equity | 1.48 | 0.28 | +1.20 |